BRAF and melanoma: A phase I/II dose escalation study combining afuresertib with trametinib in patients with advanced solid tumours observed a partial response in a patient with BRAF-wild-type melanoma, however the combination therapy was poorly tolerated with extensive adverse effects recorded [NCT01476137 (Tolcher et al., 2015)].